1 results match your criteria: "Missouri3Charles F. and Joanne Knight Alzheimer Disease Research Center[Affiliation]"
Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
JAMA Neurol
May 2016
Department of Neurology, Washington University School of Medicine, St Louis, Missouri2Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, Missouri3Charles F. and Joanne Knight Alzheimer Disease Research Center, Wash.
Importance: Synaptic loss is an early pathologic substrate of Alzheimer disease (AD). Neurogranin is a postsynaptic neuronal protein that has demonstrated utility as a cerebrospinal fluid (CSF) marker of synaptic loss in AD.
Objective: To investigate the diagnostic and prognostic utility of CSF neurogranin levels in a large, well-characterized cohort of individuals with symptomatic AD and cognitively normal controls.